Choosing the right medication for the treatment of alcoholism

  title={Choosing the right medication for the treatment of alcoholism},
  author={Helen M. Pettinati and Amanda R. Rabinowitz},
  journal={Current Psychiatry Reports},
In the past decade, scientists have made important progress toward understanding the neurobiology underlying an alcohol disorder. This knowledge has led to the development of promising pharmacotherapies that target the neural pathways involved in the brain’s reward center in such a way that the usual treatment response (via counseling) is substantially improved upon. There are now four US Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol dependence… 

Pharmacotherapy of Alcohol Dependence

Pharmacotherapy is being investigated to enhance abstinence and prevent relapse and complement interventions at a psychosocial level to develop clinically useful pharmacological treatments, which can be evaluated using large-scale clinical trials.

Pharmacotherapy of Addictive Disorders

Although no pharmacotherapies are currently approved for cocaine addiction, promising lines of research include agents that affect dopaminergic, GABAergic, serotonergic, and glutamatergic systems as well as the promise for immune therapies.

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.

A critical review of the literature on naltrexone as a pharmacotherapy for alcoholism is provided, which has the potential to identify responders on the basis of genetic variation and to use genetic tools to individualize the use of this medication.

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Overall, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.

How Imaging Glutamate, GABA, and Dopamine Can Inform the Clinical Treatment of Alcohol Dependence and Withdrawal

Research generated from neurochemical-specific imaging modalities including magnetic resonance spectrometry, positron emission tomography, and single photon emission computed tomography in studies of alcohol dependence and withdrawal is reviewed.

State-of-the-art behavioral and pharmacological treatments for alcohol use disorder

None of the treatments reviewed herein represents a so-called silver bullet for AUD, but they each have the potential to significantly improve the odds of recovery.

Survey of Addiction Specialists’ Use of Medications to Treat Alcohol Use Disorder

Compared with a survey published in 2001, in 2018 the proportion of respondents who reported using naltrexone more than doubled and addiction specialists were more confident in their use of AUD medications, rating their efficacy and safety more highly.

Neuroimaging in alcohol use disorder: From mouse to man

Together, such in vivo imaging tools have expanded the understanding of the dynamic course of alcoholism including evidence for regional specificity of the effects of AUD, hints at mechanisms underlying the shift from casual to compulsive use of alcohol, and profound recovery with sustained abstinence.

State-ofthe-art behavioral and pharmacological treatments for alcohol use disorder

Background: Alcohol use disorder (AUD) and its associated consequences remain significant public health concerns. Given that AUD represents a spectrum of severity, treatment options represent a

Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication

BackgroundAlcohol dependence comorbid with major depressive disorder poses a major challenge in the clinical setting. The results in the treatment with selective serotonin re-uptake inhibitors have



The Status of Disulfiram: A Half of a Century Later

Preliminary evidence suggests that disulfiram treatment could be a viable treatment for cocaine dependence because it was shown to reduce cocaine use among nonalcoholic, cocaine-dependent patients.

Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.

Both naltrexone and acamprosate are efficacious in reducing alcohol consumption in alcoholics, however, their specific role in alcoholism treatment remains to be more clearly defined.

Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.

Motivated individuals with moderate alcohol dependence can be treated with greater effectiveness when naltrexone is used in conjunction with weekly outpatient cognitive behavioral therapy.

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.

This is the first multicenter study of a depot formulation of naltrexone for the treatment of alcohol dependence and using a conservative intent-to-treat analysis, the study showed an advantage for the active medication.

Naltrexone in the treatment of alcoholism: a clinical review.

Predicting treatment response to naltrexone: the influence of craving and family history.

The data suggest that patients with high levels of alcohol craving or a strong family history of alcoholism are more likely to benefit from naltrexone treatment.

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Data indicate that long-acting naltrexone can be of benefit in the treatment of alcohol dependence and resulted in reductions in heavy drinking among treatment-seeking alcohol-dependent patients during 6 months of therapy.